IL111274A - Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them - Google Patents

Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them

Info

Publication number
IL111274A
IL111274A IL11127494A IL11127494A IL111274A IL 111274 A IL111274 A IL 111274A IL 11127494 A IL11127494 A IL 11127494A IL 11127494 A IL11127494 A IL 11127494A IL 111274 A IL111274 A IL 111274A
Authority
IL
Israel
Prior art keywords
hydrogen
derivatives
pharmaceutical compositions
compositions containing
alkylaminocarbonyl
Prior art date
Application number
IL11127494A
Other languages
English (en)
Other versions
IL111274A0 (en
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of IL111274A0 publication Critical patent/IL111274A0/xx
Publication of IL111274A publication Critical patent/IL111274A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11127494A 1993-10-15 1994-10-13 Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them IL111274A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
IL111274A0 IL111274A0 (en) 1994-12-29
IL111274A true IL111274A (en) 2000-11-21

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11127494A IL111274A (en) 1993-10-15 1994-10-13 Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (2) US6323195B1 (ko)
EP (2) EP0653427B1 (ko)
JP (1) JP2664344B2 (ko)
KR (1) KR0169114B1 (ko)
CN (1) CN1039911C (ko)
AT (1) ATE212348T1 (ko)
AU (1) AU696249B2 (ko)
CA (1) CA2118174C (ko)
CZ (1) CZ287071B6 (ko)
DE (1) DE69429708T2 (ko)
DK (1) DK0653427T3 (ko)
EG (1) EG20472A (ko)
ES (1) ES2171428T3 (ko)
FI (1) FI108723B (ko)
IL (1) IL111274A (ko)
NO (1) NO310415B1 (ko)
NZ (1) NZ264683A (ko)
PL (1) PL177730B1 (ko)
PT (1) PT653427E (ko)
RO (1) RO114133B1 (ko)
RU (1) RU2114850C1 (ko)
TW (1) TW363969B (ko)
ZA (1) ZA948062B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US7939522B1 (en) 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
OA11740A (en) 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
WO2000041540A2 (en) * 1999-01-11 2000-07-20 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
PT1086706E (pt) * 1999-03-31 2004-02-27 Eisai Co Ltd Composicao estabilizada que compreende um medicamento nootropico
PL201694B1 (pl) * 1999-10-26 2009-04-30 Janssen Pharmaceutica Nv Roztwór doustny zawierający galantaminę, sposób jego wytwarzania i zastosowanie
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
AU785385B2 (en) 2000-03-31 2007-03-29 Sanochemia Pharmazeutika Aktiengesellschaft Novel derivatives and analogues of galanthamin
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
EP2137192B8 (en) 2008-04-14 2014-06-11 Neurodyn Life Sciences Inc. Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
US20110098278A1 (en) * 2009-07-23 2011-04-28 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药(常熟)有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
NZ242744A (en) 1991-05-14 1997-02-24 Ernir Snorrason Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
RO114133B1 (ro) 1999-01-29
ZA948062B (en) 1995-06-06
EG20472A (en) 1999-05-31
FI944821A0 (fi) 1994-10-13
PL305456A1 (en) 1995-04-18
KR950011443A (ko) 1995-05-15
EP1020470A2 (en) 2000-07-19
NO943893D0 (no) 1994-10-14
EP0653427B1 (en) 2002-01-23
NO310415B1 (no) 2001-07-02
TW363969B (en) 1999-07-11
EP0653427A1 (en) 1995-05-17
NO943893L (no) 1995-04-18
DE69429708D1 (de) 2002-03-14
CA2118174A1 (en) 1995-04-16
IL111274A0 (en) 1994-12-29
CN1039911C (zh) 1998-09-23
CZ254694A3 (en) 1995-09-13
JPH07188240A (ja) 1995-07-25
JP2664344B2 (ja) 1997-10-15
CZ287071B6 (en) 2000-08-16
FI108723B (fi) 2002-03-15
DK0653427T3 (da) 2002-04-15
DE69429708T2 (de) 2002-08-29
ES2171428T3 (es) 2002-09-16
RU94036448A (ru) 1996-09-10
NZ264683A (en) 1998-03-25
CN1111245A (zh) 1995-11-08
ATE212348T1 (de) 2002-02-15
US5777108A (en) 1998-07-07
RU2114850C1 (ru) 1998-07-10
AU696249B2 (en) 1998-09-03
AU7581494A (en) 1995-05-04
PT653427E (pt) 2002-06-28
FI944821A (fi) 1995-04-16
PL177730B1 (pl) 2000-01-31
CA2118174C (en) 2000-01-18
EP1020470A3 (en) 2000-07-26
US6323195B1 (en) 2001-11-27
KR0169114B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
IL111274A (en) Derivatives of 6-O-demethyl galanthamine - and pharmaceutical compositions containing them
CA2092794A1 (fr) Naphtylalkylamines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GR3017243T3 (en) Antiemetic and migraine suppressing heterocyclic compounds and pharmaceutical compositions containing them.
ZA948060B (en) Galanthamide derivatives,a process for their preparation and their use as medicaments
AU1614492A (en) New peptide compound and a process for the preparation thereof
GB9104548D0 (en) Antineoplastic modified imidazoacridines
CA2017535A1 (en) Antispasmodic agents
AU6582394A (en) Novel bisoxadiazolidine derivative
HU9501664D0 (en) New cephem compounds
HU9502627D0 (en) Antitumor compositions and methods of treatment
MY109729A (en) Benzofuranylimidazole derivatives, a process for the preparation and therapeutical compositions containing the same
TW254937B (en) Benzocycloheptene derivative and process for preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
EXP Patent expired